Last reviewed · How we verify
Fremanezumab Prefilled Syringe [Ajovy]
Fremanezumab is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.
Fremanezumab is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis. Used for Migraine prevention in adults (episodic and chronic migraine).
At a glance
| Generic name | Fremanezumab Prefilled Syringe [Ajovy] |
|---|---|
| Sponsor | Beth Israel Deaconess Medical Center |
| Drug class | CGRP monoclonal antibody |
| Target | Calcitonin gene-related peptide (CGRP) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
CGRP is released during migraine attacks and contributes to pain signaling and neuroinflammation. By binding to and neutralizing CGRP, fremanezumab prevents its interaction with CGRP receptors on sensory neurons, thereby reducing migraine frequency and severity. This mechanism has been shown to be effective in both episodic and chronic migraine prevention.
Approved indications
- Migraine prevention in adults (episodic and chronic migraine)
Common side effects
- Injection site reactions
- Nasopharyngitis
- Upper respiratory tract infection
- Headache
- Antibody formation
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: